Ironwood Pharmaceuticals (NASDAQ:IRWD) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.89 and traded as high as $4.36. Ironwood Pharmaceuticals shares last traded at $4.30, with a volume of 3,500,427 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. Wall Street Zen upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $6.23.

Ironwood Pharmaceuticals Price Performance

The stock has a market capitalization of $701.16 million, a price-to-earnings ratio of 7.17 and a beta of 0.25. The stock has a 50 day moving average price of $3.83 and a 200-day moving average price of $3.89.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $106.51 million during the quarter, compared to analyst estimates of $92.11 million. Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. As a group, research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current year.

Insider Activity

In other news, Director Julie Mchugh sold 21,571 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total value of $80,459.83. Following the completion of the sale, the director directly owned 250,749 shares in the company, valued at $935,293.77. This represents a 7.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 9.30% of the stock is owned by insiders.

Institutional Trading of Ironwood Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Bank of America Corp DE raised its holdings in Ironwood Pharmaceuticals by 248.3% in the 3rd quarter. Bank of America Corp DE now owns 11,695,544 shares of the biotechnology company’s stock valued at $15,321,000 after acquiring an additional 8,337,672 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 186.6% during the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock worth $9,349,000 after purchasing an additional 4,140,439 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 144.3% during the 2nd quarter. AQR Capital Management LLC now owns 6,165,637 shares of the biotechnology company’s stock worth $4,422,000 after purchasing an additional 3,641,762 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Ironwood Pharmaceuticals by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 4,975,939 shares of the biotechnology company’s stock valued at $16,769,000 after purchasing an additional 58,603 shares in the last quarter. Finally, Marshall Wace LLP grew its position in shares of Ironwood Pharmaceuticals by 40.7% in the fourth quarter. Marshall Wace LLP now owns 4,424,002 shares of the biotechnology company’s stock valued at $14,909,000 after purchasing an additional 1,279,863 shares in the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.